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A B S T R A C T   
In December 2019, a new virus called SARS-CoV-2 was reported in China and quickly spread to other parts of the 
world. The development of SARS-COV-2 vaccines has recently received much attention from numerous re-
searchers. The present study aims to design an effective multi-epitope vaccine against SARS-COV-2 using the 
reverse vaccinology method. In this regard, structural proteins from SARS-COV-2, including the spike (S), en-
velope (E), membrane (M), and nucleocapsid (N) proteins, were selected as target antigens for epitope predic-
tion. A total of five helper T lymphocytes (HTL) and five cytotoxic T lymphocytes (CTL) epitopes were selected 
after screening the predicted epitopes for antigenicity, allergenicity, and toxicity. Subsequently, the selected HTL 
and CTL epitopes were fused via flexible linkers. Next, the cholera toxin B-subunit (CTxB) as an adjuvant was 
linked to the N-terminal of the chimeric structure. The proposed vaccine was analyzed for the properties of 
physicochemical, antigenicity, and allergenicity. The 3D model of the vaccine construct was predicted and 
docked with the Toll-like receptor 4 (TLR4). The molecular dynamics (MD) simulation was performed to evaluate 
the stable interactions between the vaccine construct and TLR4. The immune simulation was also conducted to 
explore the immune responses induced by the vaccine. Finally, in silico cloning of the vaccine construct into the 
pET-28 (+) vector was conducted. The results obtained from all bioinformatics analysis stages were satisfactory; 
however, in vitro and in vivo tests are essential to validate these results.   
1. Introduction 
In December 2019, a new virus called SARS-CoV-2 was reported in 
China and quickly spread to other parts of the world. The disease caused 
by this virus was officially named COVID-19 by the World Health Or-
ganization (WHO) [1]. The WHO has reported 119030459 cases and 2 
640349 deaths due to COVID 19, as of March 14, 2021 [2]. SARS-COV-2 
transmission pathways include direct and indirect transmission. Direct 
transmission occurs through respiratory droplets and saliva when 
coughing, sneezing, and close contact. Indirect transmission is also 
possible due to contaminated surfaces where the virus may remain and 
act as a secondary source [3,4]. The most common symptoms of 
COVID-19 are fever, cough, muscle soreness, and fatigue [5,6]. Patients 
with moderate to severe disease suffer from shortness of breath [5]. 
Moreover, bloody sputum was reported in a small percentage of patients 
[5]. Headaches and gastrointestinal symptoms such as nausea, vomiting, 
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and diarrhea are not common but may occur [7]. 
The Coronaviridae family consists of four genera, including alpha, 
beta, delta, and gamma [8]. The human coronavirus HCoV-NL63 and 
HCoV-229E belong to the alphacoronavirus genus, while HCoV-HKU-1, 
HCoV-MERS, HCoV-SARS, and HCoV-OC-43 belong to the betacor-
onavirus genus [9]. SARS-COV-2 was also classified as a betacoronavirus 
after the identification of its gene sequence [10]. Alpha and betacor-
onaviruses mainly infect mammals and cause disease in humans and 
animals [11]. On the other hand, gamma and delta coronaviruses mainly 
infect wild birds [12]. 
SARS-CoV-2 is an enveloped RNA virus, the genome of that is a 
positive single-stranded ribonucleic acid about 29.9 kb in length [13]. 
The virus genome consists of 14 open reading frames (ORFs) that encode 
27 proteins [14]. About two-thirds of the virus genome includes ORF1a 
and ORF1b, which encode 16 nonstructural proteins (NSPs) [15], while 
the remaining third of the genome contains eight accessory proteins, 
including orf14, 9b, 8b, 7b, 7a, p6, 3b, and 3a, and four structural 
proteins, including N, M, E, and S. 
The entry of SARS-COV-2 into the host cells requires the identifica-
tion of specific proteins of the cell surface that act as receptors for the S 
protein. The virus uses angiotensin-converting enzyme 2 (ACE2) as a 
cellular receptor to enter the host cell [16]. The E protein is an integral 
protein in the membrane that plays a crucial role in various stages such 
as virulence, assembly, and morphogenesis of SARS-COV-2 [17]. One of 
the significant functional components of SARS-COV-2 is the M protein, 
which plays an essential role in maintaining the size and shape of the 
virus [18]. The N protein helps to replicate and package viral RNA in the 
virus [19]. 
Despite advances in treating infectious diseases, pathogenic micro-
organisms still appear to be the greatest threat to public health. 
Although conventional vaccines have played a key role in eradicating 
some pathogens, their production methods require the cultivation of 
microorganisms [20], a time-consuming process that can only detect 
antigens that are produced in large quantities, while protein abundance 
does not mean that they are immunogenic [21], on the other hand, these 
methods will not work for uncultivable microorganisms [22]. Recent 
advancements in genome sequencing and the advent of computer 
biotechnology have led to new methods, including reverse vaccinology 
[23], which uses genetic data and computer algorithms to develop 
vaccines [24]. This method has several advantages over conventional 
Fig. 1. Flow chart of methods used for in silico design of the multi-epitope vaccine.  
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vaccinology, such as reducing the cost and time of vaccine development, 
detecting antigens found in small amounts, and allowing for the study of 
uncultivable or risky pathogens [22]. 
The development of SARS-COV-2 vaccines has recently received 
much attention from numerous researchers. This study aims to design an 
effective multi-epitope vaccine against SARS-COV-2 using the reverse 
vaccinology method. In this regard, CTL and HTL epitopes of S, M, N, 
and E proteins were predicted and linked together by appropriate 
linkers. CTxB as an adjuvant was linked to the N-terminal of the 
chimeric structure using one EAAAK linker. Subsequently, the vaccine 
candidate was evaluated for the physicochemical properties, antige-
nicity, and allergenicity. Furthermore, several analyzes were also per-
formed, including the prediction of secondary and 3D models of the 
vaccine construct, molecular docking, MD simulation, immune simula-
tion, and in silico cloning of the vaccine construct (Fig. 1). 
2. Methodology 
2.1. Retrieval of the amino acid sequence of the target proteins 
Amino acid sequences of the target proteins and adjuvant were 
retrieved from the NCBI database in FASTA format; their accession 
number are presented in Table 1. 
2.2. T-cell epitopes prediction and selection 
NetCTL 1.2 server (http://www.cbs.dtu.dk/services/NetCTL/) was 
used to predict the CTL epitopes for target proteins (S, M, N, and E) [25]. 
The sensitivity and specificity of the epitope predicted by the server are 
54–89% and 94–99%, respectively. The server predicted epitopes based 
on three strategies, including TAP transport efficiency, MHC-I binding 
peptides, and proteasomal C-terminal cleavage. In this study, 12 MHC 
class I supertypes were selected to predict CTL epitopes, and the 
threshold score for weight on C terminal cleavage, weight on TAP 
transport efficiency, and epitope identification were set at 0.15, 0.05, 
and 0.75, respectively. Using NetMHCII 2.3 server (http://www.cbs.dtu. 
dk/services/NetMHCII/), HTL epitopes were predicted [26]. The server 
used ANN to predict epitopes. In this study, HLA-DP, HLA-DR, and 
HLA-DQ alleles were selected to predict HTL epitopes, and the threshold 
was set at 2% and 10% for strong binder and weak binder, respectively. 
Since there were a large number of predicted epitopes and the vac-
cine constructs is limited in size, the best epitope should be selected from 
among them. In this regard, epitopes that had a binding affinity with 
more MHC alleles and thus cover a major population were selected [27, 
28]. A higher antigenicity score for an epitope indicates that it can play a 
significant role in initiating the immune response [29]. To ensure the 
safety of epitopes, their toxicity and allergenicity should be checked [30, 
31]. Therefore, the selected epitopes from the previous step were 
screened for antigenicity, toxicity, and allergenicity using VaxiJen v2.0 
(http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html), Tox-
inPred (https://webs.iiitd.edu.in/raghava/toxinpred/design.php), and 
AllerTOP v. 2.0 (https://www.ddg-pharmfac.net/AllerTOP/), respec-
tively. VaxiJen v2.0 classifies antigens solely based on protein physi-
cochemical characteristics without using sequence alignment. The 
accuracy of the antigenicity prediction by the VaxiJen v2.0 server is 
between 70% and 89% [32–34]. In this analysis, the virus was selected 
as the target organism, and the antigenicity threshold was set at 0.4. 
AllerTOP v2.0 server uses machine learning approaches, including auto 
and cross variance transformation, amino acid E-descriptors, and the k 
nearest neighbors to predict the allergenicity of proteins and peptides 
[35]. ToxinPred server predicts the toxicity of peptides along with their 
physicochemical properties such as molecular weight, hydropathicity, 
pI, charge, hydrophilicity, hydrophobicity, and amphipathicity [36]. 
Not all HTL epitopes are capable of inducing the production of cy-
tokines, and the cytokines produced by each may be different. IFN-γ is 
an important cytokine in innate and adaptive immune systems and ac-
tivates immune responses against bacteria, parasites, and particularly 
viruses [37,38]. Induction of IL-4 and IL-10 by HTL epitopes in the 
vaccine construct also helps activate cytotoxic T cells, macrophages, and 
B cells [39]. Therefore, the HTL epitopes were evaluated for induction of 
IFN-γ, IL-4, and IL-10. IFNepitope server (https://webs.iiitd.edu.in/ragh 
ava/ifnepitope/design.php) was used to predict IFN-γ-inducing HTL 
epitopes [40]. Furthermore, the SVM-based approach and IFN-γ versus 
other cytokine were selected to predict IFN-γ inducing epitopes. The 
ability of HTL epitopes to induce IL-4 was assessed using the IL4pred 
server (https://webs.iiitd.edu.in/raghava/il4pred/design.php) [41]. 
Subsequently, the IL-10Pred server (https://webs.iiitd.edu.in/ragh 
ava/il10pred/predict3.php) was used to evaluate HTL epitopes for 
IL-10 induction [42]. 
2.3. Vaccine design 
The selected CTL and HTL epitopes were used as the basic compo-
nents of the vaccine. The HTL epitopes were fused via GPGPG linkers, 
whereas KK linkers were used for linking CTL epitopes. The linkers 
improve the presentation of epitopes [43]. Glycine-rich linkers, such as 
GPGPG, help improve solubility and allow adjacent domains to act 
freely [44]. Furthermore, CTxB was attached by an EAAAK linker as an 
adjuvant to the N-terminal of the chimeric sequences to enhance the 
immunogenicity of the vaccine candidate. CTxB is the nontoxic segment 
(124 amino acids) of cholera toxin that can improve the cellular and 
humoral immune responses [45]. 
2.4. Evaluation of the physicochemical parameters, allergenicity, and 
antigenicity of the proposed vaccine 
ProtParam server (https://web.expasy.org/protparam/) was used to 
predict the physicochemical parameters of the vaccine, such as the 
number of amino acids, amino acid composition, molecular weight 
(MW), theoretical pI, half-life, instability index, aliphatic index, and 
grand average of hydropathicity (GRAVY) [46]. The AllerTOP v. 2.0 
server was used to evaluate the allergenicity of the vaccine. VaxiJen v2.0 
and ANTIGENpro (http://scratch.proteomics.ics.uci.edu/) were used to 
predict the antigenicity of the vaccine construct. ANTIGENpro predicts 
protein antigenicity independent of pathogens and based on the protein 
sequence. The prediction of this server is performed in two stages, based 
on five machine learning algorithms and multiple representations of the 
initial sequence [47]. 
2.5. Prediction of secondary structure 
The Prabi server (https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat. 
pl?page=/NPSA/npsa_gor4.html) was used to predict the percentage 
of the secondary structure elements of the multi-epitope vaccine. This 
server uses the GOR IV method to predict a secondary structure with a 
mean accuracy of 64.4% [48]. 
2.6. 3D model prediction, refinement, and validation of multi-epitope 
vaccine 
I-TASSER server (https://zhanglab.ccmb.med.umich.edu/ 
Table 1 
The accession number of the selected proteins for vaccine 
design.  





CTxB ACT78953.1  
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I-TASSER/) was used to predict the 3D structure of the vaccine 
construct. I-TASSER provides a platform for the prediction of high- 
quality tertiary structure models from the amino acid sequences. This 
server generates the 3D structures from the amino acid sequence by 
reassembling excised fragments from threading templates and reports a 
C-score to evaluate the accuracy of the predicted models [49–51]. 3D 
refine server (http://sysbio.rnet.missouri.edu/3Drefine/) was used to 
improve the quality of the 3D structure of the selected model [52–54]. 
Model validation is an essential step in comparing the quality of the 
unrefined model with the refined model [55]. PROCHECK (https:// 
saves.mbi.ucla.edu/), ERRAT (https://saves.mbi.ucla.edu/), and 
ProSA-web (https://prosa.services.came.sbg.ac.at/prosa.php) were 
used to validate the 3D model of the vaccine construct. PROCHECK 
generates the Ramachandran plot, showing the percentage of amino 
acids presented in the favoured, allowed, and disallowed regions [56, 
57]. ERRAT conducts a statistical analysis of non-bonded interactions 
between various atoms in protein structures [58]. ProSA-web calculates 
the overall quality score for the protein structure. If the computed score 
is outside the range characteristic of native proteins, it indicates po-
tential errors in the protein structure [59,60]. 
2.7. B-cell epitopes prediction 
The BCPred server (http://ailab-projects1.ist.psu.edu:8080/bcpred/ 
predict.html) was used to predict linear B-cell epitopes. The server 
predicts linear B-cell epitopes using a subsequence kernel-based SVM 
classifier with an accuracy of 74.57% [61,62]. In the present study, the 
vaccine sequence was used as input without changing other default 
parameter values. The Ellipro server (http://tools.iedb.org/ellipro/) 
was used to predict discontinuous B-cell epitopes utilizing residue 
clustering algorithms and Tornton’s approach [63]. In this analysis, the 
refined 3D model of the vaccine was used as input, and the minimum 
score and maximum distance were set at 0.5 and 6 Å, respectively. 
2.8. Molecular docking 
Molecular docking is a computational method used to predict the 
complex structure and interaction of ligands and receptors at the atomic 
level. Accordingly, ClusPro 2.0 server (https://cluspro.org/login.php) 
was used to perform molecular docking between the vaccine construct 
and TLR4 (PDB ID: 4G8A) [64–66]. The refined models of vaccine 
construct and TLR4 were submitted to the server as ligand and receptor, 
respectively. LigPlot software was used to map bonds formed between 
residues of vaccine construct and TLR4 in the docked complex [67]. 
2.9. MD simulation 
The GROMACS 2019.6 software was used to perform the MD simu-
lation. This software predicts the behavior of ligands and receptors over 
a period of time using Newton’s laws of atomic and molecular motion 
[68–70]. The ff99SB force field was used for the preparation of the input 
structure. Next, sodium and chlorine ions were used to neutralize the 
surface charge of the structure. Moreover, the protein was inserted into a 
layer of TIP3P water molecules with a thickness of 10 Å using gmx 
solvate software. The energy minimization of the structures was carried 
out using the steepest descent method to eliminate van der Waals in-
teractions and hydrogen bonds forming between water and complex 
molecules. Subsequently, the system temperature was gradually 
increased from 0 to 300 K with a duration of 200 ps in constant volume, 
and the system was then equilibrated at constant pressure. The MD 
simulation was performed at a temperature of 300 K and a period of 40 
ns Finally, the root mean square deviation (RMSD) and the root mean 
square fluctuation (RMSF) of the ligand and receptor were calculated. 
2.10. Immune simulation 
C-ImmSim server (http://150.146.2.1/C-IMMSIM/index.php?page 
=1) was used to characterize the immune response profile of the 
designed multi-epitope vaccine. This server is an agent-based simulator 
that predicts cellular and humoral immune responses to specific anti-
gens using the position-specific scoring matrix (PSSM) and machine 
learning approaches [71]. In this analysis, random seed, simulation 
volume, and simulation step parameters were set at 12345, 10, 270, 
respectively. Two injections with time steps of 1 and 63 were considered 
for the proposed vaccine. The rest of the parameters were kept as the 
default values [72]. 
2.11. Codon optimization and in silico cloning of the vaccine construct 
Java Codon Adaptation Tool (JCat) was used to reverse translation 
and codon optimization of the multi-epitope vaccine [73]. E. coli (strain 
K12) was selected as the host organism to express the vaccine construct. 
Moreover, cDNA sequence, codon adaptation index (CAI), and GC con-
tent were included in the server output. The CAI and GC content are 
essential parameters to evaluate the protein expression levels. Finally, 
the sequence of restriction sites for the XhoI and BamHI restriction 
enzyme was added at 5′ and 3′ ends of the nucleotide sequence of the 
vaccine, respectively, and inserted into the pET-28 (+) vector by 
SnapGene tool. 
3. Results 
3.1. T-cell epitopes prediction and selection 
A total of 443 CTL epitopes for E, M, N, and S proteins were predicted 
by NetCTL 1.2 server. Among them, epitopes with the ability to bind to 
at least four different human MHC class subtypes were assessed for 
allergenicity, antigen, and toxicity. Finally, one CTL epitope was 
selected for each of E, M, and N proteins and two CTL epitopes were 
selected for S protein (Supplementary File. 1). HTL epitopes were pre-
dicted for E, M, N, and S proteins using the NetMHCII 2.3 server. A total 
of 75 high score HTL epitopes (15-mer) with high binding potential for 
at least six human MHC II alleles were screened for antigenicity, aller-
genicity, toxicity, and induction of IFN-γ, IL-4, and IL-10. Induction of 
IL-4 and IL-10 by HTL epitopes in the vaccine construct also helps 
activate cytotoxic T cells, macrophages, and B cells [39]. One HTL 
epitope was selected for each of M, N, and S proteins, and two HTL 
epitopes were selected for E protein based on the mentioned parameters 
(Supplementary File. 2). 
3.2. Vaccine design 
A total of five CTL epitopes and five HTL epitopes were used to 
construct multi-epitope vaccines (Table 2). HTL and CTL epitopes were 
linked together by GPGPG and KK linkers, respectively. A sequence of 
150 amino acids was obtained after epitope fusion. The adjuvant 
sequence, with a length of 124 amino acids (MIKLKFGVFFTVLLS-
SAYAHGTPQNITDLCAEYHNTQIHTLNDKIFSYTESLAGKRE-
Table 2 
The selected epitopes for the final vaccine construct.  
protein CTL epitope HTL epitope 
E FLAFVVFLL (20–28) KPSFYVYSRVKNLNS (53–67) 
SFYVYSRVKNLNSSR (55–69) 
M ATSRTLSYY (171–179) WITGGIAIAMACLVG (75–89) 
N LSPRWYFYY (104–112) QIGYYRRATRRIRGG (83–97) 
S FVFLVLLPL (2-10) NFTISVTTEILPVSM (717–731) 
WTAGAAAYY (258–266)  
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MAIITFKNGATFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAK-
VEKLCVWNNKTPHAIAAISMAN), was attached to the N-terminal of the 
vaccine sequence by one EAAAK linker (Fig. 2). 
3.3. Evaluation of the physicochemical parameters, allergenicity, and 
antigenicity of the proposed vaccine 
The physicochemical characteristics of the multi-epitope vaccine 
were computed by the ProtParam server. The final composition of the 
vaccine included 279 amino acids. Cysteine and alanine were the lowest 
(1.1%) and the highest (9.3%) residues in the vaccine construct, 
respectively (Fig. 3). The molecular weight of the vaccine was 30.99 
kDa, and its theoretical pI was estimated to be 10.01. The half-life of the 
vaccine was calculated to be 30 h in mammalian reticulocytes, more 
than 20 h in yeast, and more than 10 h in E. coli. The predicted values for 
the instability index, aliphatic index, and GRAVY were 39.92, 82.9, and 
− 0.088, respectively. The non-allergic nature of the vaccine construct 
was defined by AllerTOP v. 2.0 server. The antigenicity of the vaccine 
was predicted using VaxiJen v2.0 and ANTIGENpro. The antigenicity of 
the vaccine construct predicted by the VaxiJen v2.0 server was 0.5638 
and 0.6015 in the virus and bacterial models, respectively. The ANTI-
GENpro server also estimated the probability of vaccine antigenicity at 
0.8456. These results confirmed the antigenic nature of the proposed 
vaccine. 
3.4. Prediction of secondary structure 
The percentage of the secondary structure elements of the vaccine 
was estimated using the Prabi server. The predicted structure included 
34.77% alpha-helix, 24.37% extended strand, and 40.86% random coil 
(Fig. 4). 
3.5. 3D model prediction, refinement, and validation of multi-epitope 
vaccine 
Five 3D structure models of the vaccine were generated by the I- 
TASSER server using the threading templates (PDB Hit: 1ltrA, 3chbD, 
1g55A, 4l6t, 6elcA, 1ltrF, and 5elbA). The C-scores of the models 1 to 5 
were − 4.18, − 3.73, − 4.35, − 3.36, and − 4.67, respectively. The C-score 
is usually in the range of [-5 to 2], and a high value C-score indicates a 
high confidence model [49]. Consequently, model 4 with a C-score of 
− 3.36 was selected and refined using the 3D refine server (Fig. 5), which 
generated five refined models and calculated the 3D refine score, 
GDT-TS, GDT-HA, RMSD, MolProbity, and RWPlus parameters for each 
model (Table 3). The lower values of the 3D refine score, RWplus, and 
MolProbity, and the higher values of the GDT-TS, GDT-HA, and RMSD, 
indicate higher quality models. Refined model 5 was selected based on 
the parameters mentioned above (Fig. 5). PROCHECK, ERRAT, and 
ProSA-web were used to compare the overall quality of the protein 
structure of the vaccine before and after the refining process. The 
Ramachandran plot of the initial model showed that 74.4%, 20.2%, 
2.9%, and 2.5% of the residues were present in the favoured, additional 
allowed, generously allowed, and disallowed regions, respectively 
(Fig. 6a). After refinement, 81.5%, 13.9%, 2.9%, and 1.7% of residues 
were present in the favoured, additional allowed, generously allowed, 
and disallowed regions, respectively (Fig. 6b). The ERRAT predicted the 
overall quality factor to be 79.705 for the unrefined model and 81.413 
for the refined model (Fig. 6c and d). The Z-score of the initial model was 
determined to be − 7.6 (Fig. 6e), which reached − 7.91 after the refine-
ment (Fig. 6f). 
3.6. B-cell epitopes prediction 
The BCPred server predicted five linear B-cell epitopes (20-mer) with 
scores ranging from 0.735 to 1 (Table 4). The place of the linear B-cell 
epitopes in the 3D model of the vaccine construct is shown in Fig. 7. Ten 
discontinuous B-cell epitopes were predicted by the ElliPro server 
(Fig. 8). The size of the predicted epitopes ranged from 6 to 38 amino 
acids. The lowest and highest scores for the epitopes were 0.621 and 
0.814, respectively (Table 5). 
3.7. Molecular docking 
The molecular docking was performed between the vaccine 
construct and TLR4 using the ClusPro server, which generated 26 clus-
ters. Cluster 2 was used to perform molecular dynamics simulation 
analysis due to its negative energy score (− 952.8 kcal/mol) compared to 
other clusters, indicating the highest binding affinity. In this cluster, the 
two chains, B and D from TLR4, interacted with the vaccine construct 
(Fig. 9). A total of 9 hydrogen bonds were formed between the residues 
of the chain B from TLR4 and the vaccine residues, while the number of 
hydrogen bonds formed between the residues of the chain D from TLR4 
and the residues of the vaccine was 11. (Fig. 10a and b). The amino acids 
that formed these hydrogen bonds and their distances are presented in 
Tables 6 and 7. 
Fig. 2. Schematic illustration of the multi-epitope vaccine construct.  
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3.8. MD simulation 
MD simulation was performed using GROMACS 2019.6 software to 
evaluate stable interactions between the vaccine candidate and TLR4 in 
the docked complex. The RMSD of the structures generated during the 
MD simulation in the time dimension is an appropriate and common 
standard to verify the structural stability of the protein. The RMSD value 
of TLR4 had an increasing trend at the beginning of the simulation 
period and reached 0.6 nm after 17000 ps, and then decreased to 0.3 nm 
in 24,000 ps After this time, the RMSD value increased to approximately 
0.4 nm and remained constant until the end of the simulation time. The 
RMSD plot of the vaccine showed a continuous increase up to 33,000 ps 
and reached about 0.8 nm, and remained at the same value until the end 
of the simulation (Fig. 11a). The RMSF of Cα atoms was determined to 
evaluate the motion and structural flexibility of the ligand and receptor 
in the docked complex. The RMSF plot of the vaccine showed very sharp 
fluctuations, in which the highest peaks with an RMSF value of 0.8 nm in 
the plot indicated a highly flexible region (amino acids 205–215) in the 
vaccine construct. The fluctuations in the RMSF plot of TLR4 were very 
mild. The 20 amino acids showed high flexibility at the end of chains A 
and B (Fig. 11b). 
3.9. Immune simulation 
The immune response elicitation of the multi-epitope vaccine was 
evaluated using the C-ImmSim server. The level of antigen was signifi-
cantly decreased after the first and second injections of the proposed 
vaccine. The primary response was characterized by an increase in the 
levels of IgM + IgG, IgM, and IgG1, and in the secondary response the 
levels of these antibodies increased relative to their concentrations in 
the primary response, and an increase in IgG1 + IgG2 and IgG2 was also 
observed (Fig. 12a). The B cell memory and B cell isotype IgM and IgG1 
populations were increased after each injection, and a very small pop-
ulation of B cell isotype IgG2 was also observed after the second injec-
tion (Fig. 12b). The TH cell population reached 5000 cells per mm3 from 
the first injection to day 10 and remained at the same level until the 
second injection, after that increased again, reaching 9000 on day 30, 
and then slowly decreased until day 90. Moreover, the level of TH 
memory cells increased after each injection, and the increase was higher 
Fig. 3. Amino acid composition in the vaccine construct. The vaccine sequence contains 279 amino acids, and the highest and lowest residues in the vaccine 
construct are alanine and cysteine, respectively. 
Fig. 4. Schematic illustration of the secondary structure elements of the vaccine construct. The predicted secondary structure consists of alpha-helix (34.77%) in 
blue, extended strand (24.37%) in red, and random coil (40.86%) in purple. 
Fig. 5. The initial and refined models are shown in dark magenta and gold 
colors, respectively. To compare the initial and refined models, the models were 
superimposed. 
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after the second injection (Fig. 12c). After the first injection, the TC cell 
population increased, reaching 1150 cells per mm3 on the 12th day, 
which decreased slowly until the 90th day (Fig. 12d). A significant in-
crease was observed in IFN-γ and IL-2 levels following each vaccine 
injection (Fig. 12e). The active macrophage population also increased 
after each vaccination (Fig. 12f). 
Table 3 
Results of the 3D refine server. Model 5 was selected as the best refined model based on the 3Drefine score, GDT-TS, GDT-HA, RMSD, MolProbity, and RWPlus 
parameters.  
Model 3Drefine Score GDT-TS GDT-HA RMSD (Å) MolProbity RWPlus 
5 17245.5 0.9991 0.9713 0.353 3.256 − 53105.552557 
4 17446.4 1.0000 0.9803 0.331 3.230 − 53051.739246 
3 17792.9 1.0000 0.9875 0.301 3.180 − 52958.210160 
2 18422.5 1.0000 0.9964 0.257 3.213 − 52815.241513 
1 20587.0 1.0000 0.9982 0.193 3.266 − 52650.359028  
Fig. 6. Validation of the tertiary structure of the vaccine using the Ramachandran plot, ERRAT, and ProSA-web before and after the refining process. (a) Ram-
achandran plot of the initial model shows that 74.4% of residues to be in the favoured region, (b) while in the refined model, 81.5% of residues to be in the favoured 
region. (c) The ERRAT results indicate that the overall quality factor for the initial model is 79.705, (d) while this value for the refined model is 81.413. (e) The z- 
score obtained from the ProSA-web is − 7.6 in the initial model and (f) and the z-score of the refined model is − 7.91. 
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3.10. Codon optimization and in silico cloning of the vaccine construct 
Back translation and codon optimization of the vaccine construct 
was conducted using JCat. There were 837 nucleotides in the optimized 
codon sequence. The CAI of the optimized nucleotide sequence was 
0.95, and the GC content was 49.46%. Finally, the nucleotide sequence 
of the vaccine was cloned into the pET-28 (+) vector using the SnapGene 
tool (Fig. 13).. 
4. Discussion 
The advent of the twentieth century has been accompanied by the 
emergence of new viruses, the latest case of emerging viruses was the 
SARS-COV-2 epidemic in Wuhan, China [74]. The threat of any new 
virus requires us to quickly develop a vaccine. Indeed, vaccines are one 
of the most effective ways to prevent viral infections because, in most 
cases, other treatment options are limited or non-existent, and infections 
lead to clinical deterioration, which decreases the therapeutic effect 
[75]. 
In recent months, many efforts have been made by researchers to 
develop an effective vaccine against SARS-COV-2. As of November 18, 
2020, approximately 164 SARS-CoV-2 vaccine candidates were in pre-
clinical phases, and 44 vaccine candidates were in clinical trials (phase 
I–III) [76]. The US Food and Drug Administration (FDA) granted the 
emergency use authorization for Pfizer/BioNTech and Moderna 
Table 4 
Linear B-cell epitope predicted by the BCPred server.  
Position Linear B-cell epitope Score 
203 VGGPGPGQIGYYRRATRRIR 1 
139 NLNSSRGPGPGKPSFYVYSR 1 
175 VTTEILPVSMGPGPGWITGG 0.999 
62 TFKNGATFQVEVPGSQHIDS 0.947 
99 TEAKVEKLCVWNNKTPHAIA 0.735  
Fig. 7. Linear B-cell epitopes (magenta) are shown in the 3D model of the 
vaccine construct (blue). 
Fig. 8. 3D model representation of discontinuous B-cell epitopes (a–j). The vaccine construct is shown in gray sticks, and the B-cell epitopes are depicted by yel-
low surface. 
Table 5 
Discontinuous B-cell epitope predicted by the ElliPro server.  
Position Discontinuous B-cell epitope Score 
267 LLKKLSPRWYFYY 0.814 
110 NNKTPH 0.812 
1 MIKLKFGVFFTV 0.787 
219 RRIRGGKKFV 0.733 
72 EVPGSQHID 0.715 
138 KNLNSSRGPGPG 0.693 
235 LKKWTAGAAAYYK 0.652 
31 AEYHNTQIHTLNDKIFSYTESLAGKREMAIITFKNGAT 0.648 
155 VYSRVKNLNSGPGPGNFTISVTTEILPVSMGPGPG 0.633 
124 NEAAAKS 0.621  
Fig. 9. Docked complex of vaccine construct with TLR4. The vaccine construct 
(ligand) is shown in blue, whereas tan color represents TLR4 (receptor) in the 
docked complex. 
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COVID-19 vaccines on December 11 and 18, 2020, respectively [77]. 
Simultaneously with these clinical trials, another group of researchers 
used the immunoinformatics approaches to design epitope-based vac-
cines against SARS-COV-2. In bioinformatics studies, various proteins of 
SARS-COV-2 have been used as target antigens to predict epitope. In 
studies conducted by Kar et al. [78], Dar et al. [79], and Kumar et al. 
[80], S protein alone was used as a target for epitope prediction. How-
ever, in other pieces of research conducted by Kalita et al. [81] and 
Khairkhah et al. [82], S, M, and N protein were identified as target an-
tigens. Furthermore, S, E, and N proteins were reported as target anti-
gens by Kumar et al. [83]. In addition to structural proteins, Zaheer et al. 
[84], Chauhan et al. [85], Enayatkhani et al. [86], and Jain et al. [87] 
used some accessory proteins as antigen targets in their studies. 
In the present study, as in the study of Singh et al. [88], four struc-
tural proteins, including S, M, N, and E, were used to predict epitope. 
Fig. 10. Map of interactions between vaccine construct and TLR4 generated by the LigPlot software. (a) Interactions between the vaccine construct and chain B from 
TLR4. (b) Interactions between the vaccine construct and chain D from TLR4. The hydrogen bonds are shown by the green dotted lines. 
Table 6 
List of amino acids of the vaccine and TLR4 (chain B) that formed hydrogen 
bonds.  
TLR4 (chain B)-Vaccine Number of hydrogen bonds Distance (Å) 
Glu89-Tyr279 1 2.88 
Asn44-Leu230 1 2.84 
Leu43-Ser143 1 2.88 
Gln91- Ile221 1 2.93 
Gln91- Arg222 2 2.65 
2.77 
Glu27-Arg144 2 2.60 
2.70 
Ser25-Arg144 1 2.65  
Table 7 
List of amino acids of the vaccine and TLR4 (chain D) that formed hydrogen 
bonds.  
TLR4 (chain D)-Vaccine Number of hydrogen bonds Distance (Å) 
Lys39-Tyr246 1 2.74 
Arg68-Tyr278 1 2.79 
Gln41-Arg252 1 3.03 
Gln19-Lys247 1 2.51 
Asn47-Ser272 2 2.37 
3.12 
Asn47-Arg274 1 2.76 
Val24-Arg274 1 2.77 
Ser45-Arg274 2 2.76 
2.81 
Trp23-Arg274 1 2.75  
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After screening the predicted epitopes for allergenicity, antigen, and 
toxicity, five HTL epitopes and five CTL epitopes were selected for use in 
the vaccine construct (Table 2). According to a report by Nguyen et al. 
[89], the epitopes selected in the present study were found in conserved 
regions of structural proteins and were potentially appropriate for vac-
cine development. The selected HTL and CTL epitopes were arranged in 
different orders and positions in the vaccine construct using flexible 
linkers such as GPGPG, AYY, and KK. After evaluating the physico-
chemical properties, particularly the stability of the obtained constructs, 
it was concluded that GPGPG and KK linkers are appropriate linkers for 
linking HTL and CTL epitopes, respectively. CTxB was added to the 
N-terminal of the vaccine structure as an adjuvant by the EAAAK linker 
to increase the immunogenicity of the vaccine. This adjuvant was 
selected based on previous research, which has shown that it can be used 
as a viral adjuvant to boost both systemic and mucosal immunity to the 
respiratory syncytial virus by nasal vaccination [90]. In this work, for 
the first time, the CTxB sequence and epitopes of structural proteins of 
M, N, E, and S were organized by appropriate linkers within a vaccine 
construct. 
The molecular weight of the vaccine was 30.99 kDa, due to the easier 
purification process of proteins with a molecular weight of less than 110 
kDa in the laboratory, the predicted value for this parameter is satis-
factory [91]. The theoretical pI of the vaccine was estimated to be 10.01, 
indicating that the vaccine was basic in nature. The half-life of the 
vaccine was estimated to be 30 h in mammalian, allowing the vaccine 
with a long half-life to be more exposed to the immune system [92]. The 
instability index of the vaccine candidate was estimated at 39.92, and 
since this value is less than 40, the vaccine is classified as a stable protein 
[92]. The aliphatic index was computed 82.9, indicating that the vaccine 
is thermostable [93]. The hydrophilicity of the vaccine construct in-
creases its delivery and processing, formulation, and dissolution in an 
aqueous environment [94]. The negative and positive values of GRAVY 
indicate that the vaccine construct is hydrophilic and hydrophobic, 
respectively [95]. The GRAVY score was − 0.088, indicating the hy-
drophilic nature of the vaccine due to its negative value; therefore, it can 
interact better with water molecules [96]. However, in the study of 
Qamar et al. [97], GRAVY was calculated to be 0.395, and the use of 
micelles to improve the interaction of the vaccine in the polar envi-
ronment of the body seems to be necessary due to the hydrophobic 
nature of the vaccine. 
According to these results, the physicochemical properties of the 
vaccine candidate are in accordance with the standard criteria required 
for vaccine formulation. Furthermore, the suggested vaccine was found 
to be antigenic and non-allergenic, indicating that the multi-epitope 
vaccine without an allergic reaction would have a strong immune 
response. After 3D modeling, the structure of the vaccine was refined to 
achieve a high-quality structure. The evaluation of the Ramachandran 
plot of the initial and refined model of the vaccine showed that 74.4% of 
the residues in the initial model were present in the favoured region, 
which increased to 81.5% after refining, confirming the improvement in 
the refined model. Approximately 35.8% and 22% of vaccine construct 
residues were found to be present in the linear and discontinuous B-cell 
epitopes, respectively, indicating an antiviral antibody response. 
Hu et al. showed that TLR4 expression is upregulated within 24 h 
after SARS-CoV infection, indicating its role in the generation of immune 
responses [98]. Other studies have also demonstrated the influential role 
of TLR4 in inducing immune responses against coronavirus [99–101]. 
Consequently, TLR4 was selected as the immune receptor for molecular 
docking in the present study, such as studies by Yang et al. [102] and 
Safavi et al. [103]. The molecular docking analysis showed that our 
vaccine has the ability to bind TLR4 and induce a strong immune 
response. In this regard, MD simulation of the docked complex was 
carried out for 40 ns to evaluate the stability of the vaccine structure. 
The RMSD plot of the vaccine-TLR4 complex showed the stability of the 
complex (Fig. 11a). The RMSF plot showed that the residues present in 
the HTL epitopes fluctuate more than the residues in CTL epitopes 
(Fig. 11b), which is due to the more interaction of CTL epitope residues 
with TLR4. The immune simulation results indicated that the final 
structure of the vaccine was able to activate both cellular and humoral 
immune responses against SARS-COV-2. Moreover, the secondary 
response generated by the vaccine was significantly higher than the 
primary response. Codon optimization was performed to assure the 
maximum expression of the designed vaccine in E. coli (strain K12). The 
CAI and GC content of the optimized nucleotide sequence were 0.95 and 
49.46%, respectively. CAI greater than 0.8 is optimal for expression in 
the target organism [104], and the GC content between 30 and 70% is 
considered ideal [96]. The results of the computational evaluation of the 
vaccine candidate were satisfactory; however, these results must be 
validated in both in vitro and in vivo experiments. 
5. Conclusion 
The SARS-COV-2 outbreak, first reported in China, was spread 
rapidly to other parts of the world and has recently caused heavy ca-
sualties. The vaccine appears to be the most effective way to combat this 
virus. The reverse vaccinology method can be used to design a safe and 
high potency vaccine in a short time and at a low cost. In the present 
study, bioinformatics software and online servers were used to design a 
multi-epitope vaccine against SARS-COV-2. S, E, N, and M proteins were 
selected from SARS-COV-2 as the target proteins for epitope prediction. 
After screening epitopes for antigenicity, allergenicity, and toxicity, a 
total of five CTL and five HTL epitopes and CTxB (as adjuvant) were 
organized in a multi-epitope vaccine structure. The evaluation of the 
vaccine using the ProtParam server showed that the proposed vaccine is 
of good quality regarding its physicochemical properties. The results of 
the molecular docking showed the high affinity of the vaccine construct 
with TLR4. The stability of the vaccine construct was confirmed by MD 
simulation. Furthermore, the efficacy of the vaccine to elicit an immune 
Fig. 11. MD simulation of the vaccine - TLR4 complex. (a) The RMSD plot of TLR4 shows an increasing trend from the beginning of the simulation and remains at 
about 0.4 nm from 30,000 ps to the end of the simulation. The RMSD plot of the vaccine increases from the beginning of the simulation until 33,000 ps, after that time 
it remains at approximately 0.8 nm to the end of the simulation. (b) In the RMSF plot, the peaks represent regions with a high degree of flexibility. 
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response was confirmed by immune simulation. However, these results 
must be validated in both in vitro and in vivo tests. 
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Fig. 12. Simulation of the immune response of the proposed vaccine. (a) Immunoglobulins production after the vaccine injection. (b) B cell population. (c) TH cell 
population. (d) TC cell population. (e) Concentration of cytokines and interleukins. (f) Macrophages population per state. 
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